Subclinical toxicity of calcineurin inhibitors in repeated protocol biopsies: An independent risk factor for chronic kidney allograft damage

Transplant International

Volumn 23, Issue 4, 2010, Pages 364-373

  Krejčí, Karel ^a   Tichý, Tomáš ^a   Hrubý, Miroslav ^a   Horák, Pavel ^a   Ciferská, Hana ^a   Horčička, Vladko ^a   Štrebl, Pavel ^a   Al Jabry, Sadek ^a   Bachleda, Petr ^a   Zadražil, Josef ^a  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

Author keywords

Banff chronicity score; Calcineurin inhibitors; Kidney transplantation; Protocol biopsy; Renal allograft damage; Subclinical nephrotoxicity

Indexed keywords

CALCINEURIN INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; BIOPSY; CHRONICITY; COHORT ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENAL GRAFT DYSFUNCTION; RISK FACTOR; ADOLESCENT; ALLOTRANSPLANTATION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PROCEDURES; TOXICITY;

ADOLESCENT; ADULT; AGED; BIOPSY; CALCINEURIN INHIBITORS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 77649263886     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2009.00995.x     Document Type: Article

References (22)

1. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004 4 : 1289.
2. Rush D. Protocol transplant biopsies: an underutilized tool in kidney transplantation. Clin J Am Soc Nephrol 2006 1 : 138.
3. Chapman JR, Nankivell BJ. Nephrotoxicity of ciclosporin A: short-term gain, long-term pain? Nephrol Dial Transplant 2006 21 : 2060.
4. Naesens M, Lerut E, Damme BV, Vanrenterghem Y, Kuypers DR. Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation. Am J Transplant 2007 7 : 2114.
5. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004 78 : 557.
6. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999 55 : 713.
7. Solez K, Colvin RB, Racusen LC, et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007 7 : 518.
8. Rush DN, Nickerson P, Jeffery JR, McKenna RM, Grimm PC, Gough J. Protocol biopsies in renal transplantation: research tool or clinically useful? Curr Opin Nephrol Hypertens 1998 7 : 691.
9. Viklicky O, Matl I, Voska L, et al. TGF-β1 expression and chronic allograft nephropathy in protocol kidney graft biopsy. Physiol Res 2003 52 : 353.
10. Morath C, Ritz E, Zeier M. Protocol biopsy: what is the rationale and what is the evidence? Nephrol Dial Transplant 2003 18 : 644.
11. Woywodt A, Bahlmann FH, De Groot K, Haller H, Haubitz M. Circulating endothelial cells: life, death, detachment and repair of the endothelial cell layer. Nephrol Dial Transplant 2002 17 : 1728.
12. Koo DD, Roberts IS, Quiroga I, et al. C4d deposition in early renal allograft protocol biopsies. Transplantation 2004 78 : 398.
13. Rowshani AT, Scholten EM, Bemelman F, et al. No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one zdar. J Am Soc Nephrol 2006 17 : 305.
14. Hauser IA, Schaeffeler E, Gauer S, et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005 16 : 1501.
15. Macphee IA, Fredericks S, Mohamed M, et al. Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation 2005 79 : 499.
16. Oberbauer R, Segoloni G, Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 2005 18 : 22.
17. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006 6 : 514.
18. Ekberg H, Grinyó J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007 7 : 560.
19. Mota A, Arias M, Taskinen EI, et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004 4 : 953.
20. Mulay AV, Hussain N, Fergusson D, Knoll GA. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 2005 5 : 1748.
21. Diekmann F, Budde K, Slowinski T, et al. Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria. Transpl Int 2008 21 : 152.
22. Tostivint I, du Montcel ST, Jaudon MC, et al. Renal outcome after ciclosporin-induced nephrotoxicity. Nephrol Dial Transplant 2007 22 : 880.